Derakhshan Behrad
Known title: Chief Business OfficerCIK: 0001853109
Associated companies
Transaction History
| EWTX | ▲ Buy | Option Exercise | 5,781 | $0 | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 7,500 | $0 | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,171 | $95K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 304 | $14K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 150 | $7K | 8/12/2026 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,475 | $108K | 8/12/2026 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,781 | $0 | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 2,491 | $33K | 8/12/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,691 | $28K | 5/2/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,209 | $0 | 5/1/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 10,000 | $19K | 2/5/2025 | View on chart |
| EWTX | ▼ Sell | Open Market | 10,000 | $300K | 2/5/2025 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 42,068 | $81K | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 42,068 | $1.2M | 9/20/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,718 | $32K | 5/2/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,208 | $0 | 5/1/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 4,800 | $9K | 2/9/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 4,800 | $96K | 2/9/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 4,600 | $9K | 2/8/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 4,600 | $92K | 2/8/2024 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 600 | $1K | 2/7/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 600 | $12K | 2/7/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,747 | $16K | 5/2/2023 | View on chart |
| EWTX | ▲ Buy | Option Exercise | 5,208 | $0 | 5/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.